| Today's Top Story |  |  | | | Health Care & Policy | | | | - Amgen, UCB halt development of romosozumab for fracture healing
Amgen and UCB said they would end their work on romosozumab, a humanized anti-sclerostin antibody, for fracture healing due to the results of a midstage trial and the high bar that fracture treatments must meet for approval. The firms will continue to develop the drug for the treatment of post-menopausal osteoporosis. PharmaTimes (U.K.) (2/13)       - Consortium unveils drug development project in EU
The European Lead Factory, a global consortium that includes drugmakers, research groups and academics, introduced plans for a platform that will search half a million compound libraries to help support drug discovery in Europe. The project "will give European researchers unprecedented access to industry chemical collections and facilitate the translation of their findings into actual treatments for patients," said Michel Goldman, executive director of Europe's Innovative Medicines Initiative. PharmTech.com (2/11) | Company & Financial News | | | | | Industry Deals | | | | - Bristol licenses non-Rx drugs to Reckitt Benckiser for $482M
Reckitt Benckiser is paying $482 million for rights to market some of Bristol-Myers Squibb's nonprescription medications in Latin America. The three-year deal includes the painkiller Tempra, the antacid Picot, and cough and cold drug Naldecon. After three years, Reckitt Benckiser will be given the option to acquire legal rights and intellectual property for the treatments. PharmaTimes (U.K.) (2/13) - Qiagen will develop assays for Lilly's drugs
Qiagen agreed to develop companion diagnostic tests for Eli Lilly & Co.'s experimental and approved drugs. The alliance expands Lilly's "capabilities to more quickly and cost-effectively bring innovative new medicines, alongside advanced diagnostics, to patients worldwide who are waiting," said Daniel Skovronsky, Lilly's vice president of tailored therapeutics. GenomeWeb Daily News (free registration) (2/13) | Food & Agriculture | | | | - FDA extends comment period for biotech salmon
The FDA extended until April 26 the public comment period for AquaBounty Technologies' biotech salmon, which grows twice as fast as traditional fish, after receiving nearly 30,000 responses so far. The agency will evaluate the comments and consider how to proceed, FDA spokesperson Morgan Liscinsky said. Preliminary assessments said no major environmental impact was posed by the fish. Canada.com/The Canadian Press (2/13) | Industrial & Environmental | | | | - Obama wants $2B oil revenue invested in alt-fuels program
President Barack Obama is urging Congress to steer $2 billion from oil and natural gas revenues into a new fund aimed at promoting cleaner vehicle technologies, according to a White House memo that adds details to a proposal in Tuesday's State of the Union address. "This $2 billion investment will support research into a range of cost-effective technologies -- like advanced vehicles that run on electricity, homegrown biofuels and domestically produced natural gas -- (and) will be funded by revenue generated from federal oil and gas development," the memo said. Reuters (2/13)  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| News from BIO | | | | - Are you taking full advantage of your membership?
BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here.
| SmartQuote | | | |  | Mistakes are part of the dues that one pays for a full life."
--Sophia Loren,
Italian actress  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Wednesday, February 13, 2013
- Tuesday, February 12, 2013
- Monday, February 11, 2013
- Friday, February 08, 2013
- Thursday, February 07, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment